Overview

A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

Status:
Completed
Trial end date:
2021-06-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium